APA (7th ed.) Citation

E, K., SD, K., SH, S., C, O., SJ, P., JY, C., . . . HS, Y. (2024). A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations. Integrative cancer therapies, 23, 15347354241268231. https://doi.org/10.1177/15347354241268231

Chicago Style (17th ed.) Citation

E, Kwag, et al. "A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy Between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations." Integrative Cancer Therapies 23 (2024): 15347354241268231. https://doi.org/10.1177/15347354241268231.

MLA (9th ed.) Citation

E, Kwag, et al. "A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy Between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations." Integrative Cancer Therapies, vol. 23, 2024, p. 15347354241268231, https://doi.org/10.1177/15347354241268231.